Ventricular Catheters, Thomale Catheter

K260044 · Aesculap, Inc. · JXG · Oct 2, 2026 · Neurology

Device Facts

Record IDK260044
Device NameVentricular Catheters, Thomale Catheter
ApplicantAesculap, Inc.
Product CodeJXG · Neurology
Decision DateOct 2, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.5550
Device ClassClass 2
AttributesTherapeutic, Pediatric

Indications for Use

The catheters are intended for cerebrospinal fluid (CSF) shunting.

Device Story

Ventricular catheters (Thomale Catheter) serve as components of the Miethke Shunt System for hydrocephalus treatment. Devices are implanted to provide a fluid pathway for CSF drainage. Catheters feature bullet-shaped tips with 6 or 16 inlet holes, depth markers, and radiopaque tantalum ink for visualization. Manufactured from barium sulfate-filled silicone elastomer. Used by neurosurgeons in clinical settings. Output is a physical conduit for CSF flow; clinical benefit is the management of intracranial pressure. Device articulates with existing Miethke shunt valves and reservoirs.

Clinical Evidence

Bench testing only. Performance evaluated per ISO 7197:2024, including kink testing and radiopacity. MRI safety testing performed per ASTM F2052, F2213, F2182, and F2119. Biocompatibility testing conducted per ISO 10993-1, covering cytotoxicity, sensitization, irritation, genotoxicity, implantation, acute systemic toxicity, sub-chronic toxicity, hemolysis, and pyrogenicity. Chronic toxicity and carcinogenicity addressed via chemical characterization and toxicological risk assessment.

Technological Characteristics

Materials: Barium sulfate-filled silicone elastomer (NUSIL MED14-4765, MED14-4750, MED-4860). Dimensions: 1.2 mm ID, 2.5 mm OD; 18 cm or 25 cm lengths. Features: Bullet-shaped tip, 6 or 16 inlet holes, tantalum ink depth markers. Sterilization: Steam. Connectivity: None (mechanical component).

Indications for Use

Indicated for cerebrospinal fluid (CSF) shunting in patients requiring hydrocephalus treatment, including adult, pediatric, and neonatal populations.

Regulatory Classification

Identification

A central nervous system fluid shunt is a device or combination of devices used to divert fluid from the brain or other part of the central nervous system to an internal delivery site or an external receptacle for the purpose of relieving elevated intracranial pressure or fluid volume (e.g., due to hydrocephalus). Components of a central nervous system shunt include catheters, valved catheters, valves, connectors, and other accessory components intended to facilitate use of the shunt or evaluation of a patient with a shunt.

Predicate Devices

Reference Devices

Submission Summary (Full Text)

{1} **U.S. FOOD & DRUG** ADMINISTRATION October 2, 2026 Aesculap, Inc. Kathy Racosky Technical Manager II 3773 Corporate Pkwy. Center Valley, Pennsylvania 18034 Re: K260044 Trade/Device Name: Ventricular Catheters, Thomale Catheter Regulation Number: 21 CFR 882.5550 Regulation Name: Central Nervous System Fluid Shunt And Components Regulatory Class: Class II Product Code: JXG, HCA Dated: September 2, 2026 Received: September 2, 2026 Dear Kathy Racosky: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding {2} K260044 - Kathy Racosky Page 2 When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {3} K260044 - Kathy Racosky Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, JULIA E. SLOCOMB -S Digitally signed by JULIA E. SLOCOMB -S Date: 2026.10.02 16:45:02 -04'00' for Ryan Trombetta, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260044 | ? | | Please provide the device trade name(s). | | ? | | Ventricular Catheters, Thomale Catheter | | | | Please provide your Indications for Use below. | | ? | | The catheters are intended for cerebrospinal fluid (CSF) shunting. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | Ventricular Catheters, Thomale Catheter Page 17 of 125 {5} K260044 # 510(k) SUMMARY (as required by 21 CFR 807.92) # Ventricular Catheter, Thomale Catheter October 1, 2026 COMPANY: Aesculap®, Inc. 3773 Corporate Parkway Center Valley, PA 18034 Establishment Registration Number: 2916714 CONTACT: Kathy A. Racosky 610-984-7402 (phone) kathy.racosky@aesculap.com TRADE NAME: Ventricular Catheters, Thomale Catheter COMMON NAME: Shunt, Central Nervous System And Components Catheter, Ventricular CLASSIFICATION: Class II CLASSIFICATION NAME: Central Nervous System Fluid Shunt And Components Ventricular catheter REGULATION NUMBER: 882.5550, 882.4100 PRODUCT CODE: JXG, HCA # Predicate device Ventricular Catheter, K200950 # Indications for Use The catheters are intended for cerebrospinal fluid (CSF) shunting. # Device description The Ventricular Catheter, Thomale Catheter are utilized as a component of the Miethke Shunt System(s) to treat hydrocephalus. It is available in two lengths: 18 cm or 25 cm with an inner diameter of 1.2 mm and an outer diameter of 2.5 mm. The 18 cm catheter is offered with either 6 or 16 flow holes at the proximal end, while the 25 cm catheter is supplied exclusively with 16 flow holes. To facilitate accurate placement, the Ventricular Catheter, Thomale Catheter incorporate five depth markers noted by numerical stripes at 3, 5, 7, 10 and 13 cm from the catheter tip. The Ventricular Catheter, Thomale Catheter are manufactured using barium sulfate filled silicone elastomer. The purpose of this submission is to obtain clearance for modifications to the ventricular catheter component of the Miethke Shunt System (predicate device K200950). Specifically, this Page 1 of 5 {6} K260044 submission proposes two product updates: a newly designed ventricular catheter and a variant manufactured using alternative materials. The Ventricular Catheter, Thomale Catheter are designed to articulate with existing Miethke Shunt Systems, specifically, M.blue Adjustable Shunt System, Miethke Shunt System GAV 2.0 and SA 2.0 Valves, proGAV 2.0 Adjustable Shunt System, Miethke Shunt System miniNAV valve, Miethke Shunt System (DSV, connectors, and reservoirs) cleared by FDA (K192266/K190174/K161853/K141687/K110206/K030698/K011030). # **Technological Comparison (compared to Predicate(s))** | Attributes | Subject device Ventricular Catheter, Thomale Catheter | Predicate device Ventricular Catheter K200950 | Equivalency Analysis | | --- | --- | --- | --- | | Product Code: | JXG | JXG | Identical to the predicate device. | | Class: | II | II | Identical to the predicate device. | | Regulation # | 882.5550 | 882.5550 | Identical to the predicate device. | | Indications: | The catheters are intended for cerebrospinal fluid (CSF) shunting. | The catheter is used for cerebrospinal fluid (CSF) shunting. | Equivalent The subject device is substantially equivalent to the predicate device. Although there is a slight difference in the wording of the indications for use both devices share the same intended use: to provide a fluid pathway for the shunting of cerebrospinal fluid (CSF). Aligns with FDA terminology for Indications for Use, which describes the device's purpose rather than its actual usage. | | Classification Name: | Central Nervous System Fluid Shunt and Components | Central Nervous System Fluid Shunt and Components | Identical to the predicate device. | | Catheter Body Dimensions: | 1.2 mm ID (0.050") x 2.5 mm OD (0.100") | 1.2 mm ID (0.050") x 2.5 mm OD (0.100") | Identical to the predicate device. | | Catheter Length: | 18 and 25 cm | 18 and 25 cm | Identical to the predicate device. | | Catheter Markers: | -Numerical w/stripe at 3, 5, 7, 10 & 13 cm -Stripe at 4, 6, 8, 9, 11 & 12 cm -Dot between 3.5-12.5 cm at 1 cm intervals | -Numerical w/stripe at 3, 5, 7, 10 & 13 cm -Stripe at 4, 6, 8, 9, 11 & 12 cm -Dot between 3.5-12.5 cm at 1 cm intervals | Identical to the predicate device. | | Marking: | Tantalum ink marker | Tantalum ink marker | Identical to the predicate device. | Page 2 of 5 {7} K260044 | Attributes | Subject device Ventricular Catheter Thomale Catheter | Predicate device Ventricular Catheter K200950 | Equivalency Analysis | | --- | --- | --- | --- | | **Catheter Tip:** | | | | | Ventricular Catheter | Bullet shape with 16 inlet holes (4 rows of 4 holes) | Bullet shape with 16 inlet holes (4 rows of 4 holes) | Identical to the predicate device. | | Thomale Catheter | Bullet shape with 6 inlet holes | Bullet shape with 16 inlet holes (4 rows of 4 holes) | Equivalent The subject device is substantially equivalent to the predicate device. It maintains the same bullet-shaped tip design, with a reduced number of inlet holes. | | Close-up of Catheter Marking: | | | Identical to the predicate device. | | **Close-up of Catheter Tip:** | | | | | Ventricular Catheter | | | Identical to the predicate device. | | Thomale Catheter | | | Equivalent The subject device is substantially equivalent to the predicate device. While the subject device features fewer flow holes, both devices are designed to facilitate fluid flow effectively. | | **Materials:** | | | | | Catheter tubing | - Silicone NUSIL MED14-4765 (contains Barium Sulfate BaSO₄) - Silicone NUSIL MED14-4750 (contains Barium Sulfate BaSO₄) | - Silicone NUSIL MED-4765 - Silicone NUSIL MED-2000 - Traces of Titanium Dioxide - Barium Sulfate BaSO₄ | Equivalent The subject device is substantially equivalent to the predicate device. Although it is manufactured using different materials, both devices utilize silicone elastomers. | Page 3 of 5 {8} K260044 | Attributes | Subject device Ventricular Catheter Thomale Catheter | Predicate device Ventricular Catheter K200950 | Equivalency Analysis | | --- | --- | --- | --- | | Catheter Tip | - Silicone NUSIL MED-4860 - Barium sulfate BaSO_{4} | - Silicone NUSIL MED-4860 - Barium sulfate BaSO_{4} | Identical to the predicate device. | | Marking | - NUSIL MED2-4213 (binder for markings) - Tantalum Powder | - NUSIL MED2-4213 (binder for markings) - Tantalum Powder | Identical to the predicate device. | | Specification of fillers in finished catheter | 9 – 20 % Barium Sulfate BaSO_{4} | - 9 – 20 % Barium Sulfate BaSO_{4} - Traces of Titanium Dioxide | Equivalent The subject device is substantially equivalent to the predicate device. They both have the same specification of Barium Sulfate filler in the finished catheter; both devices utilize fillers as whitening agents. | | **Sterilization:** | Steam | Steam | Identical to the predicate device. | | **Biocompatibility Assessment:** | Passed | Passed | Identical to the predicate device. | | **ISO 7197 Testing:** | Passed | Passed | Identical to the predicate device. | | **Radiopacity:** | Passed | Passed | Identical to the predicate device. | | **Endotoxin Testing:** | < 2.15 EU/device | < 2.15 EU/device | Identical to the predicate device. | ### Non-Clinical and/or Clinical Tests Summary The following performance data were provided in support of the substantial equivalence determination. Performance Bench Testing: Bench testing was conducted in accordance with ISO 7197:2024. A dedicated performance evaluation was performed under kinked conditions. Page 4 of 5 {9} K260044 Radiopacity testing was conducted on the Ventricular Catheter, Thomale Catheter. The results demonstrate that the catheters are clearly identifiable under X-ray examination. MRI Safety Testing was conducted in accordance with ASTM F2052, ASTM F2213, ASTM F2182, and ASTM F2119. The results support that the prechamber component is MR Conditional for use in 3-Tesla Magnetic Resonance Imaging systems, as defined by ASTM F2503. Biocompatibility testing: Biocompatibility evaluation was performed in accordance with ISO 10993-1 and the FDA-recognized guidance document, “Use of International Standard ISO 10993-1, Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing within a Risk Management Process.” Testing included the following endpoints: - Cytotoxicity - Sensitization - Intracutaneous Irritation/Reactivity - Genotoxicity - Implantation - Acute Systemic Toxicity - Sub-chronic Toxicity - Hemolysis - Pyrogenicity Chronic systemic toxicity and carcinogenicity endpoints were addressed through chemical characterization (extractable and leachable studies), followed by a biological risk assessment. A toxicological risk assessment was also conducted to evaluate potential risks of chronic systemic toxicity, carcinogenicity, and developmental and reproductive toxicity associated with patient exposure to extractable compounds. This assessment considered use in adult, pediatric, and neonatal populations. The Ventricular Catheter, Thomale Catheter, deflector, prechamber and CSF port are classified as implantable devices in contact with neural tissue and/or bone, cerebrospinal fluid (CSF), and blood (indirect blood contact through CSF (>30 days). The stylet is classified as an indirect contact device intended for tissue/bone contact of less than 1 hour. ## Conclusion: All testing results confirm that the Ventricular Catheter, Thomale Catheter, as a component of the Miethke Shunt System, meets the acceptance criteria for the specified shelf life, conforms to ISO 7197, and are substantially equivalent to the predicate device. Page 5 of 5
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...